Anticoagulation Practices Surrounding Emergency Department Cardioversion for Atrial Fibrillation and Flutter.
Abstract
Most patients undergoing ED cardioversion received guideline-concordant anticoagulation. However, variability in dosing and post-procedural therapy persists, particularly among low-risk patients. High revisit rates highlight the need for improved follow-up, continuity of anticoagulation, and structured care pathways following ED cardioversion.
What are the key findings of this study?
Anticoagulation helps prevent blood clots during heart procedures like cardioversion, which fixes irregular heartbeats. Many patients get the right medication, but some don't, especially those at low risk. This can lead to them returning to the hospital more often, showing that we need better follow-up care. Improved pathways for treatment can make a big difference! ❤️
Key Points
Objective
The research aims to evaluate anticoagulation practices during emergency department (ED) cardioversion for atrial fibrillation and flutter.
Methods
- Analyzed anticoagulation practices in patients undergoing ED cardioversion.
- Identified variability in dosing and post-procedural therapy among patients.
- Examined follow-up care and continuity of anticoagulation for low-risk patients.
Results
- Most patients received guideline-concordant anticoagulation prior to cardioversion.
- Notable variability in dosing and therapy was observed, especially among low-risk patients.
- High revisit rates underscore the need for better follow-up and structured care pathways.
What is the clinical evidence from this study?
Study Design
Other
Key Finding
Most patients undergoing ED cardioversion received guideline-concordant anticoagulation, but dosing variability and follow-up gaps remain, especially in low-risk patients.